Speratum Biopharma, Inc. With a focus on core technologies exclusively licensed from Baylor College of Medicine, Speratum aims to revolutionize the field of drug delivery and oligonucleotide administration. Their cutting-edge platforms have a wide range of applications and have been out-licensed for various therapeutic and research modalities.

Currently, Speratum is in the advanced pre-clinical stages of developing their lead therapeutic candidate. This candidate is a small RNA tumor suppressor designed to combat solid cancers. The company's dedicated team of talented scientists, clinicians, and executives, including Christian Marín-Müller, the Founder and CEO, and Osvaldo Vega-Martínez, the Chief Science Officer, are committed to translating breakthrough science from the lab to the bedside.

Speratum Biopharma's primary focus is on pre-clinical research and development of oligonucleotide therapeutics for cancer treatment. They are developing a multi-component therapeutic that includes a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a microRNA involved in the pathogenesis of various solid cancers. This is combined with a novel biocompatible material for efficient systemic and targeted delivery of nucleic acids.

To learn more about Speratum Biopharma and their groundbreaking technologies, you can visit their website or contact them via email at info@speratum. com